Showing results (11-20 of 434) with videos related to
Sort By:
Pageof 44
Cancer|July 13, 2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participationAjay K Nooka, Madhusmita Behera, Sagar Lonial, et al.Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.European Journal of Cancer (Oxford, England : 1990)|September 9, 2025
AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignanciesAmritpal Singh, Ajay K Nooka, Gourav Modanwal, et al.Infection Control and Hospital Epidemiology|March 24, 2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National StudyNishi N Shah, William McClellan, Christopher R Flowers, et al.Blood|February 3, 2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myelomaVikas A Gupta, Shannon M Matulis, Jason E Conage-Pough, et al.Blood Advances|January 4, 2018
CD86 regulates myeloma cell survivalCatherine M Gavile, Benjamin G Barwick, Scott Newman, et al.Oncology (Williston Park, N.Y.)|September 4, 2014
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomibAjay K NookaCancer|May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patientsAjay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.Expert Review of Hematology|May 14, 2021
Selinexor for the treatment of patients with previously treated multiple myelomaClifton C Mo, Sundar Jagannath, Ajai Chari, et al.Pageof 44